Loading...
•
Jun 30, 2025
Boston Scientific Q2 2025 Earnings Report
Boston Scientific reported strong revenue and profit growth in Q2 2025.
Key Takeaways
Boston Scientific delivered a strong Q2 2025 with revenue surpassing $5 billion, driven by significant growth in the Cardiovascular segment. GAAP net income more than doubled year-over-year, and adjusted EPS exceeded guidance.
Revenue grew 22.8% year-over-year to $5.06 billion.
GAAP net income rose to $797 million, more than doubling from last year.
Cardiovascular organic revenue grew 23.2%, leading all segments.
U.S. revenue surged 30.7%, driving overall geographic performance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Boston Scientific expects continued strong growth in 2025, with double-digit revenue expansion and higher adjusted EPS.
Positive Outlook
- Full-year revenue growth expected at 18-19% reported and 14-15% organic.
- Adjusted EPS guidance raised to $2.95–$2.99 for FY2025.
- Q3 revenue expected to grow 17-19% reported and 12-14% organic.
- Cardiovascular segment continues to drive strong organic growth.
- Successful acquisitions expanding treatment portfolio.
Challenges Ahead
- Currency fluctuations expected to negatively impact reported growth by ~0.5%.
- Integration of acquisitions may add short-term costs.
- Restructuring charges expected to continue in 2025.
- Regulatory changes such as EU MDR may increase compliance costs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...